By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ALZA Corporation (Acquired by J & J) 

1900 Charleston Road

Mountain View  California  94043  U.S.A.
Phone: 650-564-5000 Fax: 650-564-7070


ALZA Corporation, headquartered in Mountain View, California, is a leading developer and manufacturer of drug delivery based products for the global healthcare industry. ALZA's has the world's broadest array of drug delivery technology and drug targeting platforms, including oral, transdermal, implantable and liposomal technologies and applies its delivery technology to develop and manufacture pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical and biotechnology companies. More than 30 products marketed in over 80 countries worldwide now incorporate ALZA's drug delivery technologies. For additional information on ALZA, a wholly owned subsidiary of Johnson & Johnson, please visit


In 1968, Dr. Alejandro Zaffaroni founded ALZA Corporation on the vision that drug delivery technology can add value to pharmaceutical products by precisely controlling the targeting, timing, and dosing of therapeutic compounds. Today, ALZA's technologies are incorporated in over 30 products marketed by its partners in more than 80 countries around the world.

ALZA developed products have provided therapy for millions of patients throughout the world. The company's osmotically controlled oral system (OROS®), transdermal (D-TRANS®), and implantable (DUROS®) technologies have found applications in many widely used pharmaceutical products, including Duragesic® (fentanyl) CII, NicoDerm® CQ® (nicotine), Ditropan XL® (oxybutynin), Concerta® (methylphenidate) and Viadur® (leuprolide acetate). Additionally, STEALTH® liposomal technology is designed to improve efficacy and reduce toxicity of intravenous drugs via site-specific targeting.

ALZA's newer drug delivery technologies - including E-TRANS® transdermal, Macroflux® transdermal, and ALZAMER® depot injection technologies - provide multiple approaches to improving current and future therapies. These novel technologies are designed to offer convenient, comfortable alternative methods currently used to administer proteins, peptides, and new biotechnology products.

ALZA is changing the face of health care. As new compounds emerge from biotechnology and genetic research, ALZA technologies continue to evolve, providing unique delivery platforms that meet the challenges and extend the potential of important new therapies.

Last updated: 12-16-03

Key Statistics

Ownership: Public

Web Site: ALZA Corporation
Employees: 1600
Symbol: JNJ


Company News
Incline Therapeutics Announces Acquisition of IONSYS(TM) from ALZA Corporation (JNJ) and $43 Million Series A Financing 6/22/2010 9:02:44 AM
ALZA Corporation (JNJ) Faces Layoffs in Vacaville, California 11/4/2009 7:19:06 AM
McNeil Pediatrics Release: District Court Decision Received in CONCERTA(R) Patent Case 3/31/2009 11:38:44 PM
Alzheimer's Drug Discovery Foundation Appoints New Managing Director and Chief Operating Officer 10/29/2007 2:39:09 PM
ALZA Corporation (JNJ) to Cut 600 Jobs, Exit Mountain View HQ 7/31/2007 5:56:03 PM
Launch Of Macroflux Corporation In $75 Million Spin-Out From Johnson & Johnson (JNJ) 10/10/2006 9:56:31 AM
Drug Shown To Improve Common Male Sexual Problem 9/8/2006 8:32:23 AM
IMPAX Laboratories, Inc. (IPXL) Prevails In ALZA Corporation (JNJ)s Appeal Related To Generic Version Of Ditropan(R) XL 9/7/2006 2:27:47 PM
Johnson & Johnson (JNJ) To Shut Down Fremont Scios Inc. (JNJ) Unit; Lays Off 500 Workers From Scios And ALZA Corporation (JNJ) 6/23/2006 11:49:59 AM
The Day In Review: Genentech, Inc. (DNA) Gets OK To Restart Avastin Trial 5/23/2006 6:03:01 PM